NSE: MANKIND · 27 October 2026
- Mankind Pharma has risen 14.04% over 2 trading sessions; today's move is +9.14%.
- Mankind Pharma reported its consolidated financial performance for the second quarter ended September 30, 2026, posting revenue from operations of Rs 4,338 crore, a 17.3% year-on-year increase. EBITDA grew 27.2% to Rs 1,175 crore with margins expanding by 210 basis points to 27.1%, while profit after tax rose 37.7% year-on-year to Rs 716 crore. Domestic revenue (excluding consumer healthcare) increased 15.9% to Rs 3,428 crore, bolstered by solid growth across chronic and acute therapeutic segments.
- Trading volume was 3.94 times the 20-day average daily volume.
Mankind Pharma share price: 14.04% rise over 2 trading sessions
Mankind Pharma Limited shares surged 9.14% today, trading near the upper end of their intraday range between 2358.5 and 2529.8 after opening at 2358.5.
The broader market showed muted movement as the Nifty slipped 0.02%, while the Nifty Pharma sector index advanced 2.06%.
The price move coincides with the release of the company's financial results for the second quarter and half year ended September 30, 2026, filed on October 26, 2026. Management reported consolidated revenue from operations of Rs 4,338 crore, marking a 17.3% year-on-year increase, alongside a 37.7% growth in profit after tax to Rs 716 crore.
25.59 lakh shares traded by 27 October 2026 · 02:55 PM IST. This compares with a 20-day average daily volume of 6.50 lakh shares (3.94 times). The five-day average daily volume was 7.66 lakh shares. Separately, the NSE report for 26 October 2026 showed 4.56 lakh shares delivered, representing 44.46% of that day’s traded volume. The same report recorded 56,520 trades.
The sharp upward price movement and heavy cash-volume participation follow the announcement of strong financial results for the quarter ended September 30, 2026, featuring robust double-digit revenue and profit growth.
Latest Company Developments
Mankind Pharma reported its consolidated financial performance for the second quarter ended September 30, 2026, posting revenue from operations of Rs 4,338 crore, a 17.3% year-on-year increase. EBITDA grew 27.2% to Rs 1,175 crore with margins expanding by 210 basis points to 27.1%, while profit after tax rose 37.7% year-on-year to Rs 716 crore. Domestic revenue (excluding consumer healthcare) increased 15.9% to Rs 3,428 crore, bolstered by solid growth across chronic and acute therapeutic segments.
Strong quarterly financial results and margin expansion directly impact fundamental valuation and investor sentiment.
The company announced its strategic entry into next-generation CAR-T therapies through the acquisition of a majority stake in Armed Cell Therapeutics. Management noted that the transaction aims to strengthen the company's R&D capabilities for future growth in advanced biological treatments.
Expands the company's technological footprint into next-generation therapies, supporting long-term strategic growth.
a press release dated October 26, 2026, titled "Press Release on Financial Results for Q2 & H1 FY27".
Please find attached outcome of Board Meeting where Board has noted the merger of MCPPL & UAPL
Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 11.31% on 30 September 2026. This compares with 10.87% on 30 June 2026, a change of +0.44 percentage points.
The filing reported 36 MF/UTI holders.
What to Watch Next
- Execution and integration of the Armed Cell Therapeutics acquisition in next-generation CAR-T therapies
- Sustained performance of key domestic chronic and acute brands like Pantakind, Telmikind, and Pangraf
- Consumer healthcare segment recovery trends across regional markets
- Delivery volume trends and cash market participation relative to the 20-day average volume
Other Dated Coverage
- Mankind Pharma Share Price Today: Why MANKIND Is Rising 4.49% | 26 October 2026 — 26 October 2026
- Mankind Pharma Share Price Today: Why MANKIND Is Falling 2.77% | 23 October 2026 — 23 October 2026
- Mankind Pharma in Focus After Acquiring Majority Stake in Armed Cell Therapeutics | 16 October 2026 — 16 October 2026
More Mankind Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Mankind Pharma company news?
Mankind Pharma reported its consolidated financial performance for the second quarter ended September 30, 2026, posting revenue from operations of Rs 4,338 crore, a 17.3% year-on-year increase. EBITDA grew 27.2% to Rs 1,175 crore with margins expanding by 210 basis points to 27.1%, while profit after tax rose 37.7% year-on-year to Rs 716 crore. Domestic revenue (excluding consumer healthcare) increased 15.9% to Rs 3,428 crore, bolstered by solid growth across chronic and acute therapeutic segments.
How strong was Mankind Pharma’s trading volume?
25.59 lakh shares traded, 3.94 times the 20-day average daily volume. The price and volume data are dated 27 October 2026 · 02:55 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.